Resultats globals: 7 registres trobats en 0.02 segons.
Articles, 7 registres trobats
Articles 7 registres trobats  
1.
3 p, 192.6 KB Challenges and Solutions for Collecting and Analyzing Real World Data : The Eric CLL Database as an Illustrative Example / Chatzidimitriou, Anastasia (Karolinska Institutet, Stockholm) ; Minga, Eva (Institute of Applied Biosciences, Thessaloniki) ; Chatzikonstantinou, Thomas (G. Papanikolaou Hospital, Thessaloniki) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Stamatopoulos, Kostas (Karolinska Institutet, Stockholm) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan) ; Universitat Autònoma de Barcelona
2020 - 10.1097/HS9.0000000000000425
HemaSphere, Vol. 4 (september 2020)  
2.
10 p, 631.8 KB Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL : analysis from the iLLUMINATE study / Greil, Richard (Salzburg Cancer Research Institute-CCCIT, Cancer Cluster Salzburg. IIIrd Medical Department Paracelsus Medical University) ; Tedeschi, Alessandra (Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Anz, Bertrand (Tennessee Oncology. Department of Medical Oncology) ; Larratt, Loree (University of Alberta Hospital. Department of Clinical Hematology) ; Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ; Gill, Devinder (Princess Alexandra Hospital. Department of Clinical Hematology) ; Gribben, John G. (Queen Mary University of London, Barts Cancer Institute. Centre for Haemato-Oncology) ; Flinn, Ian W. (Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology. Center for Blood Cancers) ; Wang, Zhengyuan (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Cheung, Leo W. K. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Nguyen, Aaron N. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company. Biostatistics) ; Styles, Lori (Pharmacyclics LLC, an AbbVie Company. Clinical Science) ; Demirkan, Fatih (Dokuz Eylül University. Department of Hematology) ; Universitat Autònoma de Barcelona
The online version contains supplementary material available at 10. 1007/s00277-021-04536-6.
2021 - 10.1007/s00277-021-04536-6
Annals of Hematology, Vol. 100 (may 2021) , p. 1733-1742  
3.
12 p, 1.8 MB Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study / Burger, Jan A. (University of Texas MD Anderson Cancer Center. Department of Leukemia) ; Barr, Paul M. (Wilmot Cancer Institute, University of Rochester Medical Center) ; Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital) ; Owen, Carolyn (University of Calgary. Tom Baker Cancer Centre) ; Ghia, P (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ; Bairey, Osnat (Tel Aviv University. Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine) ; Hillmen, Peter (University of Leeds. The Leeds Teaching Hospitals, St. James Institute of Oncology) ; Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Center) ; Devereux, Stephen (NHS Foundation Trust. Kings College Hospital) ; Grosicki, Sebastian (Silesiam Medical University. Department of Hematology and Cancer Prevention) ; McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ; Simpson, David (North Shore Hospital) ; Offner, Fritz (Universitair Ziekenhuis Gent) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Dai, Sandra (Pharmacyclics LLC, an AbbVie Company) ; Lal, Indu (Pharmacyclics LLC, an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC, an AbbVie Company) ; Kipps, Thomas J. (UCSD Moores Cancer Center) ; Universitat Autònoma de Barcelona
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0. [...]
2019 - 10.1038/s41375-019-0602-x
Leukemia, Vol. 34 (october 2019) , p. 787-798  
4.
11 p, 1.8 MB Final analysis from RESONATE : Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma / Munir, T. (St. James's Hospital ( Dublín, Irlanda)) ; Brown, J.R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; O'Brien, Susan (UC Irvine. Chao Family Comprehensive Cancer Center) ; Barrientos, J.C. (Northwell Health Cancer Institute (Estats Units d'Amèrica)) ; Barr, P.M. (Wilmot Cancer Institute. University of Rochester Medical Center) ; Reddy, N.M. (Vanderbilt-Ingram Cancer Center) ; Coutre, Steven E (Stanford Cancer Center. Stanford University School of Medicine) ; Tam, C.S. (Peter MacCallum Cancer Centre. St. Vincent's Hospital and University of Melbourne) ; Mulligan, S.P. (Royal North Shore Hospital) ; Jaeger, U. (Division of Hematology and Hemostaseology. Medical University of Vienna) ; Kipps, T.J. (UCSD Moores Cancer Center) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Montillo, M. (Niguarda Ca' Granda Hospital) ; Burger, J.A. (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Byrd, J.C. (The Ohio State University Comprehensive Cancer Center) ; Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ; Dai, S. (Pharmacyclics LLC. an AbbVie Company) ; Szoke, A. (Pharmacyclics LLC. an AbbVie Company) ; Dean, J.P. (Pharmacyclics LLC. an AbbVie Company) ; Woyach, J.A. (The Ohio State University Comprehensive Cancer Center) ; Universitat Autònoma de Barcelona
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). [...]
2019 - 10.1002/ajh.25638
American Journal of Hematology, Vol. 94 Núm. 12 (january 2019) , p. 1353-1363  
5.
11 p, 693.2 KB ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation / Malcikova, J. (Brno, Czech Republic) ; Tausch, E. (Ulm, Germany) ; Rossi, Davide (Bellinzona, Switzerland) ; Sutton, L. A. (Stockholm, Sweden) ; Soussi, T. (Stockholm, Sweden) ; Zenz, T. (Zürich, Switzerland) ; Kater, A. P. (Amsterdam, The Netherlands) ; Niemann, C. U. (Copenhagen, Denmark) ; González De Castro, David (Belfast, UK) ; Davi, F. (Paris, France) ; Gonzalez Diaz, M. (Salamanca, Spain) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Gaidano, G. (Novara, Italy) ; Stamatopoulos, K. (Thessaloniki, Greece) ; Rosenquist, R. (Stockholm, Sweden) ; Stilgenbauer, S. (Ulm, Germany) ; Ghia, P. (Milan, Italy) ; Pospisilova, S. (Brno, Czech Republic) ; Universitat Autònoma de Barcelona
In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. [...]
2018 - 10.1038/s41375-017-0007-7
Leukemia, Vol. 32 (february 2018) , p. 1070-1080  
6.
7 p, 4.6 MB Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions / Puiggros, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ; Collado, Rosa (Hospital General Universitario de Valencia) ; Calasanz, Maria José (Servicio de Citogenética, Departamento de Genética, Universidad de Navarra, Pamplona, Spain) ; Ortega, Margarita (Hospital Universitari Vall d'Hebron) ; Ruiz-Xivillé, Neus (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rivas-Delgado, Alfredo (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Luño, Elisa (Servicio de Hematología, Hospital Universitario Central de Asturias, Oviedo, Spain) ; González, Teresa (Fundación Pública Galega de Medicina Xenómica) ; Navarro, Blanca (Hospital Clínic Universitari (València)) ; García-Malo, MaDolores (Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, IMIB-Arrixaca, Murcia, Spain) ; Valiente, Alberto (Complejo Hospitalario de Navarra) ; Hernández, José Ángel (Hospital Universitario Infanta Leonor) ; Ardanaz, María Teresa (Servicio de Hematología, Hospital Txagorritxu, Vitoria, Spain) ; Piñan, María Ángeles (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Blanco, María Laura (Institut d'Investigació Biomèdica Sant Pau) ; Hernández-Sánchez, María (Hospital Universitario de Salamanca. Centro de Investigación del Cáncer) ; Batlle-López, Ana (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Salgado Sánchez, Rocío Nieves (Laboratorio de Citogenética, Servicio de Hematología, Fundación Jiménez Díaz, Madrid, Spain) ; Salido, Marta (Institut Hospital del Mar d'Investigacions Mèdiques) ; Ferrer, Ana (Institut Hospital del Mar d'Investigacions Mèdiques) ; Abrisqueta, Pau (Hospital Universitari Vall d'Hebron) ; Gimeno, Eva (Hospital del Mar (Barcelona, Catalunya)) ; Abella Monreal, Eugenia (Hospital del Mar (Barcelona, Catalunya)) ; Ferrá, Christelle (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Terol, María José (Hospital Clínic Universitari (València)) ; Ortuño, Francisco (Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, IMIB-Arrixaca, Murcia, Spain) ; Costa, Dolors (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Carbonell, Félix (Hospital General Universitario de Valencia) ; Bosch José, Francesc Xavier (Hospital Universitari Vall d'Hebron) ; Delgado, Julio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Espinet i Solà, Blanca (Institut Hospital del Mar d'Investigacions Mèdiques) ; Universitat Autònoma de Barcelona
Genomic complexity identified by chromosome banding analysis (CBA) predicts a worse clinical outcome in CLL patients treated either with standard or new treatments. Herein, we analyzed the clinical impact of complex karyotypes (CK) with or without high-risk FISH deletions (ATM and/or TP53, HR-FISH) in a cohort of 1045 untreated MBL/CLL patients. [...]
2017 - 10.18632/oncotarget.17350
Oncotarget, Vol. 8 (april 2017) , p. 54297-54303  
7.
7 p, 550.2 KB Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation / Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ; Valcarcel, David (Hospital Universitari Vall d'Hebron) ; Martino, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ; Piñana, J. L. (Hospital Clínic Universitari (València)) ; Barba, Pere (Hospital Universitari Vall d'Hebron) ; Novelli, Silvana (Institut d'Investigació Biomèdica Sant Pau) ; Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ; Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Saavedra, Silvana (Institut d'Investigació Biomèdica Sant Pau) ; Granell, Miquel (Institut d'Investigació Biomèdica Sant Pau) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Briones Meijide, Javier (Institut d'Investigació Biomèdica Sant Pau) ; Brunet, Salut (Institut d'Investigació Biomèdica Sant Pau) ; Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
We analyze the impact of cyclosporine (CsA) levels in the development of acute graft-versus-host disease (aGVHD) after reduced intensity conditioning allogeneic hematopoietic transplantation (allo-RIC). [...]
2014 - 10.1155/2014/620682
Mediators of Inflammation, Vol. 2014 (january 2014)  

Vegeu també: autors amb noms similars
3 Moreno, C.
2 Moreno, Carlo
2 Moreno, Carlo
3 Moreno, Carlos
1 Moreno, Carlos J.
5 Moreno, Carmen
1 Moreno, Carole R.
1 Moreno, Carolina
13 Moreno, Cesar
1 Moreno, Cesar,
1 Moreno, Claudia Navarro
1 Moreno, Consuelo
1 Moreno, Cristina
1 Moreno, Cristina Soler
13 Moreno, César
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.